Barbara Tilley to Stroke
This is a "connection" page, showing publications Barbara Tilley has written about Stroke.
Connection Strength
0.670
-
Contemporary outcome measures in acute stroke research: choice of primary outcome measure and statistical analysis of the primary outcome in acute stroke trials. Stroke. 2012 Apr; 43(4):935-7.
Score: 0.164
-
Benefits of stroke treatment delivered using a mobile stroke unit trial. Int J Stroke. 2018 04; 13(3):321-327.
Score: 0.059
-
Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet. 2014 Nov 29; 384(9958):1929-35.
Score: 0.048
-
Application of beta regression to analyze ischemic stroke volume in NINDS rt-PA clinical trials. Neuroepidemiology. 2011; 37(2):73-82.
Score: 0.040
-
Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010 May 15; 375(9727):1695-703.
Score: 0.036
-
Patent foramen ovale, cardiac valve thickening, and antiphospholipid antibodies as risk factors for subsequent vascular events: the PICSS-APASS study. Stroke. 2009 Jul; 40(7):2337-42.
Score: 0.034
-
Lessons from adult stroke trials. Pediatr Neurol. 2006 Jun; 34(6):446-9.
Score: 0.028
-
Applying a phase II futility study design to therapeutic stroke trials. Stroke. 2005 Nov; 36(11):2410-4.
Score: 0.026
-
The impact of imbalances in baseline stroke severity on outcome in the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study. Ann Emerg Med. 2005 Apr; 45(4):377-84.
Score: 0.025
-
Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004 Mar 06; 363(9411):768-74.
Score: 0.024
-
Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA. 2004 Feb 04; 291(5):576-84.
Score: 0.023
-
Antiphospholipid-protein antibodies and acute ischemic stroke in the NINDS rt-PA Stroke Trial. Neurology. 2003 Oct 28; 61(8):1158-9.
Score: 0.023
-
Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke. Stroke. 2003 Aug; 34(8):e109-37.
Score: 0.023
-
Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial. Neurology. 2002 Sep 10; 59(5):669-74.
Score: 0.021
-
Lack of clinical significance of early ischemic changes on computed tomography in acute stroke. JAMA. 2001 Dec 12; 286(22):2830-8.
Score: 0.020
-
Use of odds ratio or relative risk to measure a treatment effect in clinical trials with multiple correlated binary outcomes: data from the NINDS t-PA stroke trial. Stat Med. 2001 Jul 15; 20(13):1891-901.
Score: 0.020
-
Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study. Neurology. 2000 Dec 12; 55(11):1649-55.
Score: 0.019
-
Predicting prognosis after stroke: a placebo group analysis from the National Institute of Neurological Disorders and Stroke rt-PA Stroke Trial. Neurology. 2000 Oct 10; 55(7):952-9.
Score: 0.019
-
Finding the most powerful measures of the effectiveness of tissue plasminogen activator in the NINDS tPA stroke trial. Stroke. 2000 Oct; 31(10):2335-41.
Score: 0.019